Evaluation of Low Phenylalanine Formulas

Status Active, not recruiting

Clinical Trial Summary

Ajinomoto Cambrooke has developed a PKU protein substitute that is a proprietary blend of purified Glycomacropeptide (GMP) and essential amino acids, under the brand name Glytactin®. One serving of such Glytactin® products contains 20mg or less of Phenylalanine (Phe). The aim of the proposed study is to use this purified GMP-AA-based protein substitute, with less Phe per gram of protein equivalent than other commercially available products, in children with PKU at 100% of their protein substitute intake and evaluate its efficacy and the change in blood Phe in comparison to Phe-free L-AA-based protein substitutes.

Clinical Trial Description

Study Design This is a 2-stage, 15-week randomized crossover trial. The randomized crossover design was chosen as it reduces the influence of differences among individuals; and it offers statistical efficiency (requires fewer subjects than non-crossover designs). In summary, 2 groups of 9 participants each will be assigned to either (1) sequence 1: take GMP-AA-based PS for the first 4 weeks and then take only L-AA-based Protein Substitute for 4 weeks, or (2) take only L-AA-based Protein Substitute for the first 4 weeks and then take GMP-AA-based PS for 4 weeks. At the end of the first 4 weeks, a 2-week washout period will follow with both groups only consuming L-AA-based PS. Randomization will be generated by a block randomization system and the random order will be kept within a sealed envelope. Primary research objective The principal research objective of this study is to evaluate the effect on Phe levels of a low-Phe diet combined with a purified GMP-AA-based protein substitute (containing 1 mg Phe/g Protein Equivalent), in the treatment of paediatric patients with PKU. Secondary research objectives The secondary objectives of the study aim to investigate whether there are any differences between the GMP-AA-based protein substitute and L-AA-based protein Substitute in the frequency and quantity of protein substitute intake, if any GI (gastrointestinal) symptoms occur with ingestion of the GMP-AA-based protein substitute, effect on satiety (hunger) and mood and any differences in anthropometric data. ;

Study Design

Related Conditions & MeSH terms

Phenylketonurias

Clinical Trial Details

NCT number	NCT06332105
Study type	Interventional
Source	Ajinomoto Co., Inc.
Contact
Status	Active, not recruiting
Phase	N/A
Start date	January 30, 2023
Completion date	April 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05998109` - PheCheck Feasibility Study
Not yet recruiting	`NCT04433728` - Life With Phenylketonuria. Adult Neurological Outcome of PCU Screened Patients From 1971 to 2002.
Completed	`NCT01209819` - Bone Mineral Density in Adults With Hyperphenylalaninemia	N/A
Active, not recruiting	`NCT05174559` - Additional Dietary Large Neutral Amino Acids (LNAA) for Improved Symptoms in Adult Classical Phenylktonuria (PKU)	N/A
Not yet recruiting	`NCT04969809` - Comparison of Atherogenic Risk Factors and Efficacy of Nutritional Treatment Among Adult Phenylketonuria Patients	N/A
Recruiting	`NCT04404530` - Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)
Recruiting	`NCT05827536` - Open-label, Randomized, 2-way Crossover, Monocentric, Controlled Study to Evaluate the Effect on Daily PHE Fluctuation of PKU GOLIKE Versus SoC in Patients With PKU.	N/A
Active, not recruiting	`NCT05971563` - Amino Acid Kinetics of GMP-AA in Healthy Human Volunteers	N/A
Enrolling by invitation	`NCT03655223` - Early Check: Expanded Screening in Newborns
Completed	`NCT04368624` - PKU Skin Stripping
Completed	`NCT04452513` - A Prospective Clinical Study of Phenylketonuria (PKU)
Completed	`NCT05497050` - The Effect of Nursing Empowerment Program	N/A
Completed	`NCT04943393` - Remote Neurocognitive and Psychological Assessment in PKU
Completed	`NCT05096988` - Evaluation of PKU Sphere Liquid	N/A
Completed	`NCT00225615` - A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels	Phase 3
Recruiting	`NCT05128149` - Metabolic Control and Patient Well-being in Phenylketonuria: do Guidelines Make a Difference?
Terminated	`NCT05229549` - Study to Evaluate the Effect on Nitrogen Retention of Two Different Posology Schemes of PKU GOLIKE PLUS 3-16 and Free AAs in Patients With Phenylketonuria	N/A
Enrolling by invitation	`NCT05356377` - Preliminary Study of Brain Effects of Palynziq-Related Changes in Phenylalanine in Individuals With PKU
Not yet recruiting	`NCT06332807` - AAV Gene Therapy Clinical Study in Adult Classic PKU	Phase 1/Phase 2
Not yet recruiting	`NCT06337864` - Evaluating the Efficacy and Safety of Large Neutral Amino Acids in the Treatment of Classical Phenylketonuria	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.